A 52-year-old woman with dilated cardiomyopathy (ejection fraction 28%) presents with recurrent episodes of palpitations. Holter monitor shows frequent premature ventricular contractions (PVCs) and runs of non-sustained ventricular tachycardia (NSVT) lasting 8–10 beats. Electrolytes are normal, and troponin is negative. She is already on a beta-blocker and ACE inhibitor. What is the most appropriate next step in management?

Explanation

## Clinical Context: NSVT in Dilated Cardiomyopathy **Key Point:** This patient has dilated cardiomyopathy with severely reduced EF (28%) and documented NSVT. This constellation is a **major risk factor for sudden cardiac death (SCD)** and warrants ICD evaluation for primary prevention. ## Risk Stratification in DCM with NSVT | Parameter | Patient's Status | Risk Significance | |-----------|------------------|-------------------| | EF | 28% | Severely reduced (< 35%) | | Arrhythmia | NSVT (8–10 beats) | Documented, repetitive | | Symptoms | Palpitations | Symptomatic | | Baseline therapy | Beta-blocker + ACE-I | Optimal medical therapy | | Troponin | Negative | No acute ischemia | **High-Yield:** In patients with **EF ≤ 35% + NSVT**, ICD is indicated for **primary prevention of SCD**, regardless of whether the NSVT is symptomatic or asymptomatic. This is a Class IIa recommendation in most guidelines. ## ICD Indication Pathway ```mermaid flowchart TD A[Dilated cardiomyopathy]:::outcome --> B{EF ≤ 35%?}:::decision B -->|Yes| C{Ischemic or non-ischemic?}:::decision B -->|No| D[Medical management only]:::action C -->|Ischemic| E{NSVT or EPS inducible?}:::decision C -->|Non-ischemic| F{NSVT present?}:::decision E -->|Yes| G[ICD indicated]:::action E -->|No| H[Consider other risk factors]:::decision F -->|Yes| I[ICD Class IIa]:::action F -->|No| J[Medical therapy, close follow-up]:::action ``` ## Why ICD Evaluation is Correct 1. **Guideline-based:** ACC/AHA and ESC guidelines recommend ICD for primary prevention in non-ischemic cardiomyopathy with EF ≤ 35% and NSVT. 2. **Mortality reduction:** ICD reduces SCD risk by ~30% in this population. 3. **Optimal medical therapy already in place:** Beta-blocker and ACE-I are already prescribed; further pharmacological optimization is unlikely to prevent SCD in NSVT + reduced EF. 4. **NSVT as a marker:** Documented NSVT in the setting of reduced EF is a strong independent predictor of SCD. **Clinical Pearl:** Do not confuse NSVT in reduced EF (which warrants ICD) with isolated PVCs in normal EF (which do not). This patient has both NSVT and severely reduced EF—a high-risk combination. [cite:Harrison 21e Ch 297; ACC/AHA 2019 Focused Update on Arrhythmias]